ANG Lifesciences Intrinsic Value
ANG Lifesciences (ANG) median intrinsic value is ₹72.42 from 3 valuation models (range ₹58–₹72), vs current price ₹28.97 — +150.0% upside (Trading Below Calculated Value), margin of safety 60.0%. Browse ANG Lifesciences financial data for revenue, profit, balance sheet and cash flow data.
ANG Valuation Methods Summary — DCF, Graham Number & P/E
ANG Lifesciences intrinsic value across 3 models vs current price ₹28.97 — upside/downside and value range per method. For current market price and key ratios, visit ANG Lifesciences stock price NSE.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹72.42 | ₹65.18 - ₹79.66 | +150.0% | Book Value/Share: ₹49.23, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹57.94 | ₹52.15 - ₹63.73 | +100.0% | Revenue/Share: ₹80.00, P/S: 2.0x |
| Simple DCF (5Y) | dcf | ₹72.42 | ₹57.94 - ₹86.90 | +150.0% | CF Growth: 4.0%, Discount: 15% |
ANG Intrinsic Value vs Market Price — All Valuation Models
ANG Lifesciences fair value range ₹58–₹72 vs current market price ₹28.97 across 3 valuation models. Also explore ANG Lifesciences share price performance to track price trends across different timeframes.
ANG Intrinsic Value Analysis — Undervalued or Overvalued?
ANG Lifesciences median intrinsic value ₹72.42, current price ₹28.97 — Trading Below Calculated Value by 150.0%, margin of safety 60.0%.
What is the intrinsic value of ANG?
Based on our comprehensive analysis using 3 different valuation methods, the estimated intrinsic value of ANG Lifesciences (ANG) is ₹72.42 (median value). With the current market price of ₹28.97, this represents a +150.0% variance from our estimated fair value.
The valuation range spans from ₹57.94 to ₹72.42, indicating ₹57.94 - ₹72.42.
Is ANG undervalued or overvalued?
Based on our multi-method analysis, ANG Lifesciences (ANG) appears to be trading below calculated value by approximately 150.0%.
ANG Financial Health — Key Ratios vs Industry Benchmarks
ANG Lifesciences financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 7.32 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | -18.8% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Asset Turnover Ratio | 0.45x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
ANG Cash Flow Quality — Operating & Free Cash Flow
ANG Lifesciences operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹0 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-10 Cr | ₹-10 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹26 Cr | ₹22 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹25 Cr | ₹3 Cr | Positive Free Cash Flow | 7/10 |